Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > SPCEO1
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by PinnacleXon Jul 31, 2023 12:12pm
122 Views
Post# 35564921

RE:RE:RE:RE:SPCEO1

RE:RE:RE:RE:SPCEO1
Kd5513 wrote:
Always good to see pop back up every few months pinnacle, u make me laugh. U must be from Canada with your allowed to talk comment, (but here in US we get to say what we want :) ) Glad to see u brought it down to a mine is bigger than yours mindset.....too funny maybe it is maybe it isnt, all we know is we have all lost money, and most of us are looking at the possibility this grows in valuation; otherwise not sure why here.



We have more freedom here in Canada then you idiots in the states that are trying to figure out what a woman is.  Its YOU no "u" you incoherent American idiot, who bought a Canadian company LOL. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities